Explore surgeries / ACL Reconstruction Explained
New research, guidelines and FDA decisions, each with a note on what it might change in a conversation with your surgeon, how certain it is, and links to the original sources.
How we choose news. Nothing here is sponsored. Mentioning a product isn't an endorsement, and an FDA clearance means a device was found substantially equivalent to existing ones, not proven better. Updated November 2026.
A matched study of 71 pairs of patients found ACL repairs failed in 15.5% by five years, compared with 4.2% for reconstruction. Ten of the 11 repair failures were in patients under 40.
What this could change in a conversation with your surgeon: ACL repair is being marketed as a less invasive option. For younger people in pivoting sports, reconstruction still has the better track record.
Sources: Healio
A prospective multicenter study of 211 growing children found only small changes in leg alignment after growth-plate-sparing and transphyseal ACL reconstruction, with no growth problems needing treatment.
What this could change in a conversation with your surgeon: Parents worry about surgery on growing knees. This supports current techniques, while showing why follow-up X-rays still matter.
Sources: Healio
In 41 athletes under 40 with high-grade knee looseness, adding a lateral extra-articular tenodesis to ACL reconstruction gave better knee scores and less laxity at 12 months than reconstruction alone.
What this could change in a conversation with your surgeon: It adds to larger studies supporting LET in high-risk patients, but this trial was small and short.
Sources: ReachMD summary
A study presented at the 2026 AAOS meeting followed 155 patients with a mean age of 56 for about six years after reconstruction and found high satisfaction and low failure rates. The authors note their patients were carefully selected and active.
What this could change in a conversation with your surgeon: Age alone shouldn't rule out surgery for an active older adult with an unstable knee.
Sources: AAOS Now
The FDA cleared updated labeling for Miach's BEAR implant. The company says pooled six-year data from its BEAR I and II studies showed lower rates of arthritis on X-ray than hamstring-graft reconstruction in patients 14 and older.
What this could change in a conversation with your surgeon: Arthritis after ACL injury is common. The data come from two company-sponsored studies with relatively small numbers, so ask your surgeon how it applies to you.
Sources: FDA record K251214 · News summary
The FDA cleared an expanded indication for the BEAR implant, adding partial ACL tears and expanding use in children and adolescents.
What this could change in a conversation with your surgeon: More people may be offered ACL restoration as an alternative to reconstruction, so it's worth understanding the trade-offs.
Sources: MassDevice
See news across every procedure on the Informed Surgery news page.